CRISPR Therapeutics: Assessing The Recent Capital Financing
۵M shares recently issued and expected to close on Jan. 08.
The said capital financing is prudent and strategic to fund their potential breakthrough.
This is an abbreviated version of the in-depth Integrated BioSci Report available in advance to our marketplace subscribers.
The reason why the growth stocks do so much better is that they seem to show gains in value in the hundreds of percent each decade. In contrast, it is an unusual bargain that is as much as 50 percent undervalued. The cumulative effect of this simple arithmetic should be obvious.
– Philip Fisher (the Father of Growth Investing)
On Jan. 05, 2018, the share price of CRISPR Therapeutics (NASDAQ:CRSP), a bioscience focusing on gene-editing and CAR-T to treat serious conditions such as cancers and genetic diseases, continued its rally. The stock added another $2.90 (over 12% profits) to value at $26.81 for the said trading session. Since we recommended the company on Nov. 27, 2017 (just over a month) to subscribers of Integrated BioSci Investing, the stock added another $7.26 (or 37% in capital appreciation). This robust run-up is interesting because, on Jan. 04, 2018, the company announced that the 5M additional common shares issued on Jan. 03 will be priced at $22.75.